NCT07192120 - A Study of MHB048C in Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

200

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

October 31, 2029

Study Completion Date

October 31, 2029

Conditions

mCRPC (Metastatic Castration-resistant Prostate Cancer)Advanced Malignant Solid Tumor

Interventions

DRUG

MHB048C for Injection

IV administration of MHB048C Q2W or Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.

Trial Locations (1)

Unknown

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai